The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20081760: Anixter International Inc.; James M. Lindenberg
20081758: American Industrial Partners Capital Fund IV, LP; Morgenthaler Partners VIII, L.P.
20081753: Infosys Technologies Limited; Axon Group plc
20081752: Sumner M. Redstone; NextMedia Investors LLC
20081751: Clayton, Dubilier & Rice Fund VII, L.P.; Bodycote Plc
20081745: Audax Private Equity Fund III, L.P.; Mobilex Acquisition Group, LLC
20081744: The Gap, Inc.; Blue Highways Holdings LLC
20081741: Sterling Investment Partners II, L.P.; Charles M. Simon
20081731: Newco; Dufry AG
20081730: Dufry AG; Newco
20081727: Audax Private Equity Fund III, L.P.; Andrews Holding, LLC
Financial Advisors & Associates Inc. also d/b/a Freedom Financial , et al.
20081746: Riverside Capital Appreciation Fund V, L.P.; Commercial Markets Holdco, Inc.
20081743: Covanta Holding Corporation; Ridgewood Electric Power Trust V
20081719: Chesapeake Energy Corporation; Cinco County Barnet Shale, LLC
20081665: Owens & Minor, Inc.; Mr. George Burrows
Sun Pharmaceutical Industries Ltd., In the Matter of (Taro Pharmaceuticals)
The Commission charged that Sun Pharmaceutical Industries Ltd’s proposed acquisition of Taro Pharmaceuticals Industries, Ltd would substantially reduce competition, likely resulting in higher prices for three distinct generic formulations of the anticonvulsant drug carbamazepine, used widely as an antiepileptic and to prevent and control seizures. The proposed deal would have reduced the number of drug suppliers to a level where the number of competitors has a direct and substantial impact on prices. In order to remedy these concerns, Sun agreed to divest all of its rights and assets needed to develop three generic forms of carbamazepine: 1) immediate-release tablets; 2) chewable tablets; and 3) extended-release tablets.